Shanghai RAAS (002252.SZ): "SR604 Injection" enters Phase III clinical trials.

Zhitong Finance APP News, Shanghai RAAS (002252.SZ) announced that its investigational product "SR604 Injection" recently had its Phase III clinical trial registration information for "preventive treatment of bleeding episodes in hemophilia A/B patients" publicly disclosed on the National Medical Products Administration's Drug Clinical Trial Registration and Information Disclosure Platform. Trial name: A single-arm, multicenter Phase III clinical trial evaluating the efficacy and safety of SR604 Injection in preventive treatment of hemophilia A/B patients with or without inhibitors. Trial objective: To evaluate the efficacy of SR604 Injection in preventive treatment of hemophilia A/B patients with or without inhibitors.